Regorafenib Assessment in Refractory Advanced Colorectal Cancer(RegARd-C)
Read time: 1 mins
Last updated:28th Jul 2013
The general objectives are to evaluate activity and the safety of regorafenib in a population of patients bearing advanced, refractory colorectal cancers and to explore the different downstream molecular pathways to identify tumor response and resistance mechanisms.
|Study start date||2013-07-28|